贫血对肿瘤患者的影响及治疗  

Anemia of tumor patients: Impact and treatment

作　　者：李博[1] 石远凯[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院肿瘤研究所内科,北京100021

出　　处：《癌症进展》2007年第3期269-275,共7页Oncology Progress

摘　　要：贫血是肿瘤患者常见的合并症,但是临床医师和患者对其认识却远远不足。贫血可以对肿瘤患者的生活质量产生负面影响。而且,贫血还可以加重肿瘤细胞低氧。其结果是引起肿瘤细胞在基因水平发生改变,诱导侵袭性表型的产生,进而造成肿瘤耐药和进展。目前已经有多项临床研究证明了重组人促红细胞生成素(rhEPO)可以有效提高患者的血红蛋白水平,减少患者的输血风险,并有效治疗患者的疲劳状态,改善肿瘤患者的生活质量。而对肿瘤患者尽早开始抗贫血治疗,改善患者对治疗的依从性,去除影响rhEPO疗效的因素,可进一步提高rhEPO的治疗效果。Anemia is a common problem among patients with malignant disease. However, it is often under- recognized by both patients and doctors. Anemia has negative impact on cancer patients＇ quality of life. Furthermore, it may also contribute to tumor resistance and progression by aggravating tumor cell hypoxia, which induces genome changes and aggressive phenotype selection. Many studies have proved that recombinant human erythropoietins （rhEPO） can increase hemoglobin rapidly, decrease the risk of emergency transfusion need, treat fatigue effectively and improve quality of life. And early intervention, improving patients＇ compliance and dealing with factors compromising rhEPO efficacy can optimize response to rhEPO.

关 键 词：贫血 肿瘤 促红细胞生成素 治疗 

分 类 号：R730.6[医药卫生—肿瘤] R730.53[医药卫生—临床医学]